Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

IntroductionAnaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC). Second- and third-generation ALKi, including alectinib, brigatinib, ensartinib, envonalkib, and lorlatinib, have shown better efficacy than crizo...

Descrición completa

Detalles Bibliográficos

Principais autores:	Vera Damuzzo, Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Alessandro Inno, Andrea Messori
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Oncology
Assuntos:	NSCLC ALK-inhibitors IPDfromKM indirect comparison Shiny method
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1566816/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!